As Novo Nordisk and Eli Lilly struggle to keep up with soaring demand for their popular diabetes and weight loss drugs, healthcare companies are introducing supply trackers to help patients navigate ongoing shortages.
Senator Bernie Sanders (I-VT) is taking aim at one of Big Pharma’s newest cash cows: the latest generation of effective obesity medications.
Pharmaceutical company Eli Lilly is making a plea to some of its customers: stop hoarding our weight loss drugs. In a new Oscar-themed commercial set to run on TV this weekend, the drugmaker is not-so-subtly telling people to stay away from its new blockbuster medications if they’re only looking to lose a few pounds.…
Another year, another round of inscrutable price increases for many prescription drugs. Over 700 medicines are seeing their list prices shoot up this January, according to an analysis by the organization 46brooklyn Research. The average price increase is slightly below the trend of recent years, but includes popular…
New research shows that tirzepatide, the latest FDA-approved obesity drug, really can help people lose substantial amounts of weight—but only if they continue taking it. The study found that people who stopped taking tirzepatide after 36 weeks regained much of their lost weight within a year, while those who continued…
There’s officially a new and fierce competitor for Novo Nordisk’s Wegovy (semaglutide) when it comes to weight loss. On Wednesday, the Food and Drug Administration approved the drug tirzepatide, developed by Eli Lilly, as a treatment for obesity. The weekly injectable drug will be sold under the brand name Zepbound.
Health officials in Austria are the latest to warn the public to stay away from sketchy sources of semaglutide, the active ingredient in popular weight loss drugs Wegovy and Ozempic, following recent reports of severe adverse effects linked to counterfeit products. Residents have reportedly been hospitalized with…
The makers of two popular but off-label weight loss drugs are now being sued over complications allegedly linked to their use. This week, a Louisiana woman filed a complaint against the companies Novo Nordisk and Eli Lilly, arguing that they have misled patients about the risk of severe gastrointestinal side effects…